(Q37877618)

24 August 2017

title

Genetic testing in the European Union: does economic evaluation matter? (English)

1 reference

24 August 2017

Fernando Antoñanzas

1

1 reference

24 August 2017

R Rodríguez-Ibeas

2

1 reference

24 August 2017

M F Hutter

3

1 reference

24 August 2017

R Lorente

4

1 reference

24 August 2017

C Juárez

5

1 reference

24 August 2017

M Pinillos

6

1 reference

24 August 2017

publication date

20 May 2011

1 reference

The European Journal of Health Economics

24 August 2017

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

651-661

1 reference

Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Randomized trial of a specialist genetic assessment service for familial breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Economic analyses of human genetics services: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost effectiveness of antenatal screening for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

BRCA1 mutations in southern England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Economic evaluations in the EURONHEED: a comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

EuroGentest: DNA-based testing for heritable disorders in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost effectiveness of a new strategy to identify HNPCC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Methodologic quality of cost-effectiveness analyses of surgical procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Evaluation of laboratory methods for cystic fibrosis carrier screening: reliability, sensitivity, specificity, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Scope of definitions of genetic testing: evidence from a EuroGentest survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Genetic screening by DNA technology: a systematic review of health economic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Testing for BRCA1 mutations: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Appraisal of a new scheme for prenatal screening for Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost effectiveness of DNA diagnosis for four monogenic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Screening for cystic fibrosis and its evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Costs, effects, and savings of screening for cystic fibrosis gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost-effectiveness ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Factors affecting the uptake of screening: A randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Trade-offs in prenatal detection of Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-011-0319-X

Prenatal screening for cystic fibrosis: an economic analysis

21 January 2018

1 reference

12 December 2020

Population genetic screening programmes: principles, techniques, practices, and policies

1 reference

12 December 2020

The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study

1 reference

12 December 2020

Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women

1 reference

12 December 2020

Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients

1 reference

12 December 2020

Genotype-based screening for hereditary haemochromatosis. I: Technical performance, costs and clinical relevance of a German pilot study

1 reference

12 December 2020

Current impact of gene technology on healthcare. A map of economic assessments

1 reference

12 December 2020

Issues in implementing prenatal screening for cystic fibrosis: results of a working conference

1 reference

12 December 2020

[Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)]

1 reference

12 December 2020

A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study

1 reference

12 December 2020

Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study

1 reference

12 December 2020

[Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia]

1 reference

12 December 2020

[Screening of cancer of the prostate (IV). Economic approach: the costs of screening tests and treatment. Members of the Sub-Committee of the Prostate of CCAFU]

1 reference

12 December 2020

Preconception cystic fibrosis carrier screening: costs and consequences

1 reference

12 December 2020

Costs and Effects of Prenatal Screening Methods for Down Syndrome and Neural Tube Defects

1 reference

12 December 2020

Health economics and genetic service development: a familial cancer genetic example

1 reference

12 December 2020

A cost-benefit analysis of prenatal diagnosis by amniocentesis in Denmark.

1 reference

12 December 2020

Screening for activated protein C resistance before oral contraceptive treatment: a pilot study

1 reference

12 December 2020

Rapid prenatal diagnostic testing for Down syndrome only or longer wait for full karyotype: the views of pregnant women

1 reference

12 December 2020

[Cost-effectiveness in diagnosis and treatment of carcinomas of unknown primary origin]

1 reference

12 December 2020

Optimal strategies for mapping complex diseases in the presence of multiple loci

1 reference

12 December 2020

Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin

1 reference

12 December 2020

10.1007/S10198-011-0319-X

Identifiers

DOI

1 reference

24 August 2017

1 reference